Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331516 | 0.90 | SMN1; SMN2 (0.37) | MEN1KMT2AALDH1A1SMN1; SMN2HTR3A | |
| SCHEMBL13093850 | 0.83 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL7002165 | 0.82 | P2RY14 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL332743 | 0.81 | MEN1 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL333010 | 0.80 | MEN1 (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL331565 | 0.80 | KMT2A (0.38) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL331607 | 0.79 | MEN1 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL331457 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL332681 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL332118 | 0.76 | CFD (0.31) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | MEN1 702/4885KMT2A 4632/4885ALDH1A1 851/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | MEN1 702/4885KMT2A 4632/4885ALDH1A1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.